Quick answerIn documented research protocols the 10 mg BPC-157 + TB-500 blend vial is typically reconstituted with 3 mL of bacteriostatic water, with the literature describing 600 mcg drawn per dose from the prepared solution. These reference reconstitution figures are provided strictly for research-use-only purposes, not medical guidance.
Fixed ratio: BPC-157 5 mg : TB-500 5 mg — a 1:1 blend. Every withdrawal keeps that ratio, so the components cannot be dosed independently.
Reconstitution calculator
Mix & measure BPC-157 + TB-500 · 10 mg
Pre-filled with this protocol’s recommended BAC water and documented starting dose — edit any field to run your own numbers.
Vial strengthmgBAC watermLYour dose
Concentration—mg/mL
Draw volume—mL
On the syringe—units
Doses / vial—
Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Full reconstitution guide → · Advanced calculator →
Dosing & Reconstitution Guide
A single practical dilution of the combined vial, with accurate once-daily dosing, step by step
i
Important: Start with the Prep & Injection Guide — it covers the preparation and safety basics every protocol on this site assumes.
Standard / Gradual Approach (3 mL = 3.33 mg/mL total blend)
▪
Reconstitute: Add 3.0 mL bacteriostatic water to one 10 mg blend vial → final concentration 3.33 mg/mL total (1.67 mg/mL of each peptide).
▪
Typical daily range: 600–1000 mcg total blend once daily (300–500 mcg of each peptide), over an 8–12 week course. One draw delivers a 1:1 BPC:TB-500 split.
▪
Easy measuring: At 3.33 mg/mL, 1 unit = 33.3 mcg total (16.67 mcg of each peptide) on a U-100 syringe. The 3.0 mL dilution keeps every dose at 18 units or more for accurate measuring.
▪
Storage: Lyophilized: store at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and do not freeze the mixed solution.
Phase / Week(s) Total Blend (1× daily) Each Peptide Volume (U-100 / mL) Weeks 1–2 600 mcg 300 mcg BPC + 300 mcg TB-500 18 units (0.18 mL) Weeks 3–4 800 mcg 400 mcg BPC + 400 mcg TB-500 24 units (0.24 mL) Weeks 5–8 600 mcg 300 mcg BPC + 300 mcg TB-500 18 units (0.18 mL)
Advanced / Aggressive Approach (Acute-Injury Support)
For acute soft-tissue research scenarios, some protocols front-load a higher dose for the first four weeks before tapering to maintenance. Robust human dose-finding data do not exist for this blend; use with caution.
Phase / Week(s) Total Blend (1× daily) Each Peptide Volume (U-100 / mL) Weeks 1–2 1000 mcg 500 mcg BPC + 500 mcg TB-500 30 units (0.30 mL) Weeks 3–4 800 mcg 400 mcg BPC + 400 mcg TB-500 24 units (0.24 mL) Weeks 5–8 600 mcg 300 mcg BPC + 300 mcg TB-500 18 units (0.18 mL)
Note
The only combined-use human data is a small, low-quality intra-articular case series at higher, different-route doses[8] — it does not validate this subcutaneous blend. Treatment is generally limited to 8–12 weeks before cycling off to evaluate response.
Ask what generic AI won't
ChatGPT dodges your BPC-157 + TB-500 dosing questions. OpenPeptide answers them.
Documented protocols, exact reconstitution math, and real sources — no lectures, no dead ends.
Why researchers study it
Why BPC-157 + TB-500 draws research interest
These are the directions researchers and the peptide community most often explore BPC-157 + TB-500 for — so you know you’re in the right place. They describe what is being studied, not proven benefits, approved uses, or promised results.
Soft-tissue & injury repair
The primary reason this blend is sought; both peptides are studied in animal models of tendon, ligament and muscle healing.
Inflammation modulation
Investigated in preclinical research for effects on inflammatory pathways around tissue injury; animal-only, not clinically validated.
Gut & GI protection
BPC-157 is explored in rodent studies of gut-lining and ulcer healing; investigational, with no approved human indication.
Angiogenesis & recovery
Researched in animal models for new blood-vessel formation thought to support recovery; preclinical evidence only.
Evidence ranges from early laboratory work to clinical trials depending on the use — the sections below cover the actual data and sources.
01 · Dosing & reconstitution
Frequency: one subcutaneous injection each day for 8–12 weeks (optionally extended to 16). Because the vial is co-formulated 1:1, every dose drawn delivers an equal split of BPC-157 and TB-500. These figures come from reference protocols, not from approved human dosing — the combination itself is not clinically validated.
Reconstitution Steps
1
Draw 3.0 mL of bacteriostatic water into a sterile syringe.
2
Release it slowly down the vial’s inner wall to limit foaming.
3
Swirl or roll gently until fully dissolved — don’t shake.
4
Label with the date and concentration, then refrigerate at 2–8 °C (35.6–46.4 °F), shielded from light.
Note
The 3.0 mL dilution keeps each dose at 18 units or more, where U-100 syringe markings are most precise. Avoid freezing the reconstituted solution, since freeze–thaw can denature the peptide.
02 · What you’ll need
Supplies Needed
Quantities below assume an 8–16 week course of once-daily injections with phased dosing (averaging ~700 mcg total blend per day across the cycle).
✓Peptide Vials (BPC-157 + TB-500, 10 mg blend each)
One 10 mg blend vial covers roughly two weeks at the averaged ~700 mcg/day, so plan about one vial every two weeks.
8 weeks: ~4 vials 12 weeks: ~6 vials 16 weeks: ~8 vials
✓Insulin Syringes (U-100, 1 mL)
Per injection: 1 syringe 8 weeks (once daily): ~56 syringes 16 weeks (once daily): ~112 syringes
✓Bacteriostatic Water (10 mL bottles)
Use ~3.0 mL per 10 mg blend vial for reconstitution.
8 weeks (4 vials): ~12 mL → 2 bottles 16 weeks (8 vials): ~24 mL → 3 bottles
✓Alcohol Swabs
One for the vial stopper + one for the injection site each day.
Per injection: 2 swabs 8 weeks (once daily): ~112 swabs → 1–2 boxes
Dosing Protocol
A suggested daily titration approach based on common reference doses.
▪Cycle Length: Typically 8–12 weeks; optional extension to ~16 weeks. ▪Timing: Inject at a consistent time each day and rotate injection sites systematically. Each draw delivers a 1:1 BPC:TB-500 ratio.
Storage Instructions
Correct storage is what preserves the peptide’s stability and activity.
▪Lyophilized: Hold the dry vial at −20 °C (−4 °F) in dry, dark conditions and limit moisture exposure[7]. ▪Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F) and use within about 28 days; do not freeze the mixed solution, as freezing can denature peptides[8]. ▪Handling: Let frozen vials warm to room temperature before opening so condensation won’t form, and keep the solution clear of heat and direct light. ▪Freeze–thaw: Avoid repeated freeze–thaw cycles of the reconstituted solution.
03 · Good to know
Important Notes
Practical points that keep daily administration safe and consistent.
▪Sterile technique: Use a fresh sterile U-100 insulin syringe each time and drop it straight into a puncture-proof sharps container afterward. ▪Site rotation: Move between abdomen, thighs and upper arms to reduce local irritation and lipohypertrophy[9]. ▪Slow injection: Push the plunger slowly and pause a few seconds before withdrawing the needle to prevent backflow. ▪Recordkeeping: Log the daily dose, injection site and any observations to keep the protocol consistent. ▪Regulatory note: Both BPC-157 and TB-500 are prohibited by WADA for athletic use and are not FDA-approved for human administration; eligibility for compounding (regulatory status remains in flux through 2026) is not the same as approval[10].
04 · How it works
How This Works
This is a single co-formulated vial holding two unrelated research peptides at a fixed 1:1 ratio — 5 mg of each, 10 mg total.
BPC-157 is a stable 15-amino-acid peptide derived from a human gastric protein. In preclinical models it has been associated with cytoprotection, modulation of nitric-oxide pathways and angiogenesis, with reported activity across gastrointestinal, musculoskeletal and other tissues[1][2].
TB-500 is a synthetic fragment of Thymosin Beta-4 whose core proposed action is the sequestering of G-actin to regulate actin polymerization — the process behind cell migration in wound healing — and which has been linked preclinically to angiogenesis and reduced inflammation[3][4].
The rationale for combining them is complementary mechanisms: BPC-157 for trophic and anti-inflammatory effects, TB-500 for cell migration and angiogenesis[8]. This rationale is theoretical.
Important caveat: the combination is not clinically validated. The only combined-use human data is a small, low-quality intra-articular case series at higher, different-route doses — not this subcutaneous blend. Musculoskeletal “recovery” claims rest on animal data and anecdote and should be read as hypotheses.
Neither peptide is an approved medicine. Both are unapproved research chemicals presented here for research and educational purposes only.
05 · Daily habits
Lifestyle Factors
Habits that may support recovery alongside the protocol.
▪Nutrition: Keep protein intake adequate to give tissue repair the building blocks it needs. ▪Activity & rest: Pair appropriate movement with real recovery time and avoid overtraining during an injury-recovery phase. ▪Sleep: Aim for 7–9 hours to support the body’s natural repair processes. ▪Stress: Manage stress with evidence-based practices, since it influences overall healing.
06 · What to expect
Potential Benefits & Side Effects
What preclinical and veterinary literature describe; human evidence is limited and individual results vary.
Potential Benefits
▪Soft-tissue repair (preclinical): Animal studies of the individual peptides report faster wound healing via enhanced angiogenesis and cell migration[5][6]. ▪Inflammation & cytoprotection (preclinical): BPC-157 shows gastroprotective and anti-inflammatory effects, and thymosin pathways are linked to reduced inflammation, in animal models[11]. ▪Tolerability (veterinary): Generally well tolerated in veterinary studies, with occasional mild injection-site reactions. ▪Note on humans: These benefits are not established in humans, and the BPC-157 + TB-500 combination is not clinically validated — no controlled trials of this blend have been completed[13].
Common Side Effects
▪Injection-site reactions: Mild redness, tenderness or soreness can occur; rotating sites helps. ▪Unknown long-term profile: Human safety data is limited, so caution and monitoring are advised. ▪Sport restriction: Both BPC-157 and TB-500 are WADA-prohibited substances for athletes.
07 · Injection technique
Injection Technique
General subcutaneous technique, following established clinical best-practice guidance[14][15].
Pre-Injection Preparation
▪Wash your hands well with soap and water. ▪Wipe the vial stopper with an alcohol swab and let it air-dry. ▪Choose a site (abdomen, thigh, or upper arm) and clean it with a fresh alcohol swab, letting it dry fully[15]. ▪Draw the intended dose, then check for air bubbles and push any out.
Injection Procedure
▪Pinch a skinfold at the chosen site between thumb and forefinger. ▪Insert the needle into the pinch at a 45–90-degree angle (use 45 degrees if the fat layer is thin)[14]. ▪Skip aspiration for subcutaneous shots — it isn’t needed[14]. ▪Press the plunger slowly and steadily until it’s fully down. ▪Wait 5–10 seconds, then pull the needle straight out to prevent leakage.
Post-Injection Care
▪Drop the used syringe straight into a puncture-proof sharps container — never recap a needle. ▪Return the reconstituted vial to the fridge right away. ▪Rotate the injection site each day to prevent irritation and lipohypertrophy[9]. ▪Watch the site for excess redness, swelling, or signs of infection.
08 · Where to source
Recommended Source
For high-purity research peptides, we point researchers to Prime Lab Peptides for the BPC-157 + TB-500 (5 mg + 5 mg) blend vial.
Why Prime Lab Peptides?
▪Top-rated on Trustpilot: Independently reviewed as the highest-rated peptide lab on Trustpilot — making it the best current source in the USA. ▪Third-party tested: Every batch ships with a Certificate of Analysis (COA) confirming purity and composition. ▪Consistent quality: ISO-aligned manufacturing and handling keep product integrity reliable batch to batch. ▪Cold-chain integrity: Temperature-controlled shipping and storage across the whole fulfilment chain. ▪Research-grade purity: Fit for educational and research use that demands high-quality peptides.
Note: Product availability and specifications subject to change. Verify current product details on supplier website.
Shop at Prime Lab Peptides →
09 · The evidence
References
1
Journal of Physiology & Pharmacology
BPC-157 (Body Protection Compound): pentadecapeptide from gastric juice with cytoprotective and wound-healing activity in preclinical models.
View Source ↗ 2
Journal of Chromatography A (PubMed)
Doping-control analysis of TB-500 as a synthetic thymosin beta-4 fragment in biological samples.
View Source ↗ 3
WADA Scientific Research
Investigation of TB-500 metabolism, synthesis of its metabolites, and detection limits.
View Source ↗ 4
Racing Medication & Testing Consortium
Thymosin beta-4 regulatory bulletin covering TB-500 use in equine sports medicine.
View Source ↗ 5
Journal of Investigative Dermatology (PubMed)
Thymosin beta-4 accelerates wound healing in a preclinical model.
View Source ↗ 6
FASEB Journal (PubMed)
Active-site mapping of thymosin beta-4 fragments for angiogenesis and cell migration.
View Source ↗ 7
Peptide Storage Guide
Best practices for storing lyophilized peptides (temperature, humidity and light protection).
View Source ↗ 8
BPC-157 + TB-500 Case Series (PubMed)
Small, low-quality case series of combined BPC-157 and TB-500 for joint injury at higher, intra-articular doses; not a controlled trial.
View Source ↗ 9
NCBI Bookshelf
Best practices for subcutaneous injection: aseptic technique and site rotation.
View Source ↗ 10
WADA Prohibited List
Classification of TB-500 as a prohibited substance in competitive sport.
View Source ↗ 11
Journal of Investigative Dermatology
Thymosin beta-4 wound-healing mechanisms: collagen deposition, angiogenesis and granulation tissue.
View Source ↗ 12
Journal of Chromatography B (PubMed)
Quantification of TB-500 metabolites and screening of wound-healing activity (prodrug hypothesis).
View Source ↗ 13
ClinicalTrials.gov
Trial registry for full-length thymosin beta-4 (e.g., dermal and ocular indications); no completed efficacy trials of the TB-500 fragment.
View Source ↗ 14
Centers for Disease Control and Prevention (CDC)
Subcutaneous injection technique: angle, site and no-aspiration guidance.
View Source ↗ 15
Subcutaneous Injection Technique (Patient Education)
How to administer a subcutaneous injection: clinical technique guidelines.
View Source ↗ 16
Prime Lab Peptides
TB-500 (5 mg) product page — purity specifications and certificates of analysis.
View Source ↗